{"date":"2026-08-31","count":23,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4726-2026-08-31-2134-1xgr9oa","company_id":"4726","company":"永昕","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"21:34:18","subject":"公告Regeneron Pharmaceuticals, Inc.向智慧財產及商業法院撤回對本公司之起訴","clause":"第53款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：永昕（4726），2026-08-31 21:34，「公告Regeneron Pharmaceuticals, Inc.向智慧財產及商業法院撤回對本公司之起訴」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6734-2026-08-31-2125-1idan58","company_id":"6734","company":"安盛生","market":"興櫃","industry":"生技醫療","date":"2026-08-31","time":"21:25:29","subject":"公告本公司115年7月份自結財務報告之負債比率、流動比率、速動比率、預估未來三個月現金收支情形及銀行可使用融資額度情形","clause":"第44款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：安盛生（6734），2026-08-31 21:25，「公告本公司115年7月份自結財務報告之負債比率、流動比率、速動比率、預估未來三個月現金收支情形及銀行可使用融資額度情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4905-2026-08-31-1924-m6euw9","company_id":"4905","company":"台聯電","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"19:24:13","subject":"公告本公司召開115年線上法說會","clause":"第12款","fact_date":"2026-09-01","cite_as":"公開資訊觀測站重大訊息：台聯電（4905），2026-08-31 19:24，「公告本公司召開115年線上法說會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4735-2026-08-31-1830-p67uuk","company_id":"4735","company":"豪展","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"18:30:09","subject":"公告本公司內部稽核主管異動","clause":"第8款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：豪展（4735），2026-08-31 18:30，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4737-2026-08-31-1742-13qqg7g","company_id":"4737","company":"華廣","market":"上市","industry":"生技醫療","date":"2026-08-31","time":"17:42:07","subject":"公告本公司法人董事辭任","clause":"第6款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：華廣（4737），2026-08-31 17:42，「公告本公司法人董事辭任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6496-2026-08-31-1657-15n1fg","company_id":"6496","company":"科懋","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"16:57:45","subject":"公告本公司審計委員會、薪資報酬委員會委員辭任","clause":"第6款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：科懋（6496），2026-08-31 16:57，「公告本公司審計委員會、薪資報酬委員會委員辭任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6496-2026-08-31-1657-qrsqda","company_id":"6496","company":"科懋","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"16:57:05","subject":"公告本公司獨立董事辭任","clause":"第6款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：科懋（6496），2026-08-31 16:57，「公告本公司獨立董事辭任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6814-2026-08-31-1638-1pzjlpi","company_id":"6814","company":"路迦生醫","market":"興櫃","industry":"生技醫療","date":"2026-08-31","time":"16:38:49","subject":"公告本公司預估未來三個月現金收支情形及銀行可使用融資額度情形","clause":"第44款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：路迦生醫（6814），2026-08-31 16:38，「公告本公司預估未來三個月現金收支情形及銀行可使用融資額度情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4744-2026-08-31-1634-s2hviw","company_id":"4744","company":"皇將","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"16:34:53","subject":"公告本公司董事會決議推舉施郭鳳珠女士為榮譽董事長","clause":"第53款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：皇將（4744），2026-08-31 16:34，「公告本公司董事會決議推舉施郭鳳珠女士為榮譽董事長」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4744-2026-08-31-1632-pawka5","company_id":"4744","company":"皇將","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"16:32:06","subject":"公告本公司會計主管、代理發言人異動","clause":"第8款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：皇將（4744），2026-08-31 16:32，「公告本公司會計主管、代理發言人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4745-2026-08-31-1631-b1ixfc","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"16:31:17","subject":"代子公司康君諮詢管理(上海)公告累計處分理財產品達公告標準","clause":"第20款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2026-08-31 16:31，「代子公司康君諮詢管理(上海)公告累計處分理財產品達公告標準」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4736-2026-08-31-1627-u5c6g5","company_id":"4736","company":"泰博","market":"上市","industry":"生技醫療","date":"2026-08-31","time":"16:27:19","subject":"代重要子公司福爾聯合(股)公司公告除息基準日相關事宜","clause":"第14款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：泰博（4736），2026-08-31 16:27，「代重要子公司福爾聯合(股)公司公告除息基準日相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4736-2026-08-31-1626-97lgxw","company_id":"4736","company":"泰博","market":"上市","industry":"生技醫療","date":"2026-08-31","time":"16:26:55","subject":"代子公司喬聯科技股份有限公司公告董事會決議解散清算其轉投資之大陸子公司蘇州喬陽醫學科技有限公司","clause":"第51款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：泰博（4736），2026-08-31 16:26，「代子公司喬聯科技股份有限公司公告董事會決議解散清算其轉投資之大陸子公司蘇州喬陽醫學科技有限公司」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7837-2026-08-31-1616-1wshgwv","company_id":"7837","company":"啟新生","market":"興櫃","industry":"生技醫療","date":"2026-08-31","time":"16:16:45","subject":"公告本公司董事會決議通過解除經理人競業禁止之限制","clause":"第22款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：啟新生（7837），2026-08-31 16:16，「公告本公司董事會決議通過解除經理人競業禁止之限制」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4102-2026-08-31-1612-y1d8tg","company_id":"4102","company":"永日","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"16:12:09","subject":"代重要子公司台灣味群工業股份有限公司公告辦理115年第一次現金增資發行新股相關事宜—修改事項","clause":"第11款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：永日（4102），2026-08-31 16:12，「代重要子公司台灣味群工業股份有限公司公告辦理115年第一次現金增資發行新股相關事宜—修改事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2026-08-31-1604-nct01n","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2026-08-31","time":"16:04:18","subject":"本公司受邀參加凱基證券舉辦之法人座談會","clause":"第12款","fact_date":"2026-09-02","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2026-08-31 16:04，「本公司受邀參加凱基證券舉辦之法人座談會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7876-2026-08-31-1533-3cgi30","company_id":"7876","company":"鼎晉生技","market":"興櫃","industry":"生技醫療","date":"2026-08-31","time":"15:33:11","subject":"公告本公司受邀參加玉山證券舉辦之實體法人說明會","clause":"第30款","fact_date":"2026-09-08","cite_as":"公開資訊觀測站重大訊息：鼎晉生技（7876），2026-08-31 15:33，「公告本公司受邀參加玉山證券舉辦之實體法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2026-08-31-1528-erh3ws","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2026-08-31","time":"15:28:00","subject":"公告本公司發言人異動。","clause":"第11款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2026-08-31 15:28，「公告本公司發言人異動。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2026-08-31-1522-pjv405","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2026-08-31","time":"15:22:28","subject":"公告本公司會計主管及發言人異動。","clause":"第11款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2026-08-31 15:22，「公告本公司會計主管及發言人異動。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4726-2026-08-31-1435-p67uuk","company_id":"4726","company":"永昕","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"14:35:07","subject":"公告本公司內部稽核主管異動","clause":"第8款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：永昕（4726），2026-08-31 14:35，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4194-2026-08-31-1140-162o6d6","company_id":"4194","company":"禾生技","market":"興櫃","industry":"生技醫療","date":"2026-08-31","time":"11:40:54","subject":"本公司115年現金增資認股基準日等相關事宜(補充委託代收及存儲款項機構)","clause":"第9款","fact_date":"2026-08-31","cite_as":"公開資訊觀測站重大訊息：禾生技（4194），2026-08-31 11:40，「本公司115年現金增資認股基準日等相關事宜(補充委託代收及存儲款項機構)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4905-2026-08-31-1044-1xyqq6v","company_id":"4905","company":"台聯電","market":"上櫃","industry":"生技醫療","date":"2026-08-31","time":"10:44:32","subject":"代重要子公司欣德芮(股)公司公告股東會重要決議事項","clause":"第18款","fact_date":"2026-06-30","cite_as":"公開資訊觀測站重大訊息：台聯電（4905），2026-08-31 10:44，「代重要子公司欣德芮(股)公司公告股東會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2026-08-31-0625-clxe5b","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-08-31","time":"06:25:57","subject":"公告美國食品藥物管理局(FDA)對LBS-007急性白血病之第一/二期臨床試驗設計變更無提出意見","clause":"第44款","fact_date":"2026-08-28","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-08-31 06:25，「公告美國食品藥物管理局(FDA)對LBS-007急性白血病之第一/二期臨床試驗設計變更無提出意見」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}